

Phase-I-Studien
Studien offen für Accrual
Klinik für Med. Onkologie und Hämatologie
Kantonsspital St. Gallen

EKSG / BASEC	Titel der Studie	PI	Bemerkungen	E-Mail PI
All comer Studien				
BASEC: 2016-00707	SAKK 67/15 BASILEA / CDI-CS-003: An open-label Phase 1/2a study of BAL101553 administered as intravenous 48-hour infusions in adult patients with advanced solid tumors Expansion Kohorten offen: <ul style="list-style-type: none"> • Histologically-confirmed <u>ovarian, fallopian-tube or primary-peritoneal cancer</u> that is newly platinum-resistant or refractory • A histologically-confirmed <u>Glioblastoma</u> in first relapse. 	MJ	Expansion offen, Slots vorhanden	Markus.Joerger@kssg.ch
2017-00921	MP0274 A phase 1, first-in-human, single-arm, multi-center, open-label, repeated-dose, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors HER2-positive solid tumor malignancy. IHC3 can be enrolled, IHC2 need FISH to confirm positivity	AO	Slots auf Anfrage	Aurelius.Omlin@kssg.ch Dagmar.Hess@kssg.ch
2017-01310	A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma	MJ	6 slots für DLBCL (IO-naiv), 2 slots HNSCC (IO-vorbehandelt), 1 slot für NSCLC (IO-naiv)	Markus.Joerger@kssg.ch
2017-02227	An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas	MJ	Slots für HER2- BC, Endometrium, Ovar, alle Biomarker-selektiert	Markus.Joerger@kssg.ch
2018-00641	SAKK 65/16 TLD-1, a novel Liposomal Doxorubicin, in Patients with Advanced Solid Tumors; a multicenter open-label single-arm phase I trial.	DH	All comers; slots auf Anfrage	Dagmar.Hess@kssg.ch
2018-02302	A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers. (CA027-002)	MJ	Studie bis auf weiteres „on hold“.	Markus.Joerger@kssg.ch

Phase-I-Studien
Studien offen für Accrual
Klinik für Med. Onkologie und Hämatologie
Kantonsspital St. Gallen

EKSG / BASEC	Titel der Studie	PI	Bemerkungen	E-Mail PI
Haematological and Lymphoma				
2015-00091	<p>EDO S101-1001 Phase-I-study of EDO S101 (alkylating histone deacetylase inhibition fusion molecule) in relapsed/refractory hematologic malignancies</p> <p>Expansion cohort 1: relapsed/refractory multiple myeloma Expansion cohort 2: relapsed/refractory Hodgkin's lymphoma Expansion cohort 3: relapsed/refractory peripheral T-cell lymphoma (PTCL) Expansion cohort 4: relapsed/refractory cutaneous T-cell lymphoma (CTCL), subtypes mycosis fungoides (MF) and Sézary syndrome (SS) Expansion cohort 5: relapsed/refractory T-cell Prolymphocytic leukemia (T-PLL)</p>	CD DH	Studie bis auf weiteres „on hold“.	Christoph.Driessen@kssg.ch Dagmar.Hess@kssg.ch

Lung Cancer				
2016-01900	<p>SAKK 19/16: Binimetinib, pemetrexed and cisplatin, followed by maintenance with binimetinib and pemetrexed, in patients with advanced non-small cell lung cancer with KRAS mutations: A multicenter phase IB trial.</p>	MF	1 slot	Martin.Frueh@kssg.ch

Melanoma				
2019-01847 CTU17.0 22	<p>ENiGMA: Open label, non-randomized, Phase IB study to characterize safety, tolerability and recommended dose of Tinostamustine (EDO-S101), a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic MelAnoma</p>	MJ	Studie bis auf weiteres „on hold“.	markus.joerger@kssg.ch

Stand: 04.09.2019 DH/AO/MJ/ KK